Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome

Table 3 Abdominal pain severity, quality of life, and perceived stress scores over the intervention period

	Placebo (n = 104)	L. plantarum 1B (n = 104)		L. plantarum 10B (n = 99)
	mean (SD)	mean (SD)	P vs Placebo1	mean (SD)	P vs Placebo1	P vs 1B dose2
APS-NRS score
Day 0	7.14 (0.69)	7.14 (0.77)		7.17 (0.86)
AbsΔ (Day 28)	-0.61 (1.12)	-0.87 (1.06)	0.1356	-0.92 (0.90)	0.0733	0.7089
AbsΔ (Day 56)	-0.94 (1.36)	-1.83 (1.38)	< 0.0001	-2.39 (1.47)	< 0.0001	0.0057
IBS-QoL total score
Day 0	36.19 (17.97)	37.83 (17.25)		37.54 (17.02)
AbsΔ (Day 28)	4.20 (14.19)	8.82 (17.38)	0.0208	17.65 (19.47)	< 0.0001	0.0009
AbsΔ (Day 56)	4.90 (14.29)	17.47 (19.54)	< 0.0001	28.78 (23.64)	< 0.0001	0.0003
PSS score
Day 0	22.06 (4.29)	22.42 (4.12)		21.93 (4.31)
AbsΔ (Day 28)	-0.12 (3.92)	-2.38 (4.54)	< 0.0001	-2.76 (4.69)	< 0.0001	0.5690
AbsΔ (Day 56)	-0.46 (4.14)	-4.33 (6.51)	< 0.0001	-5.59 (6.43)	< 0.0001	0.1708

¹ANCOVA using Dunnett’s test adjustment with treatment as factor and baseline as covariate vs placebo.

²Two-sample t-test comparing dose groups.

APS-NRS: Abdominal pain severity-numeric rating scale; IBS-QoL: Irritable bowel syndrome-quality of life; PSS: Perceived stress scale; AbsΔ: Absolute change; L. plantarum: Lactiplantibacillus plantarum.